Polarity protein SCRIB interacts with SLC3A2 to regulate proliferation and tamoxifen resistance in ER+ breast cancer

Estrogen receptor (ER) positive breast cancer represents 75% of all breast cancers in women. Although patients with ER+ cancers receive endocrine therapies, more than 30% develop resistance and succumb to the disease, highlighting the need to understand endocrine resistance. Here we show an unexpect...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Yasuhiro, Matsuda, Shiori, Ohnishi, Naomi, Endo, Keiko, Ashitani, Sanae, Ohishi, Maki, Ueno, Ayano, Tomita, Masaru, Ueda, Koji, Soga, Tomoyoshi, Muthuswamy, Senthil K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061724/
https://www.ncbi.nlm.nih.gov/pubmed/35501367
http://dx.doi.org/10.1038/s42003-022-03363-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061724/
https://www.ncbi.nlm.nih.gov/pubmed/35501367
http://dx.doi.org/10.1038/s42003-022-03363-3

Ejemplares similares